WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company has been invited to participate in a panel discussion on nanomedicines development at the NanoBusiness2010. This event is taking place today at 2pm CDT at the 9th annual NanoBusiness Conference, held at the McCormick Place in Chicago, IL.
The panel, entitled “NanoMedicine: Science, Business and Regulatory Perspectives,” is composed of experts from Industry, Government, and Academia. It is chaired and moderated by Dr. Mostafa Analoui, Head of HealthCare and Life Sciences at the Livingston Securities, NY. Dr. Diwan will discuss the current developments at NanoViricides, Inc., and the opportunities and challenges in bringing our nanoviricide® drugs to market.
This is the 9th annual conference on the business of nanotechnology organized by the NanoBusiness Alliance. The NanoBusiness Alliance mission is to create a collective voice for the advancing nanotechnology industry and develop a range of initiatives to support the nanotechnology business community.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Dengue fever, Rabies and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
Amanda Schuon, 310-550-7200
KEYWORDS: United States North America Connecticut Illinois
INDUSTRY KEYWORDS: Health AIDS Biotechnology Infectious Diseases Pharmaceutical Other Health Research Science General Health